Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial

Abstract Prognosis of adult patients with relapsed/refractory (r/r) or measurable residual disease (MRD)–positive B-precursor acute lymphoblastic leukemia (B-ALL) remains poor. Blinatumomab induces complete remissions (CR) and MRD negativity in a subset of patients, yet overall survival remains limi...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Lars Fransecky, Walter Fiedler, Christoph Röllig, Tim Sauer, Simon Raffel, Winfried Alsdorf, Lisa Heberling, Britta Steer, Karin Huber, Tim Versteegen, Lea Spory, Dorothee Deckbar, Lena Reiser, Sonja Bendig, Lorenz Bastian, Cecilia Bozzetti, Thomas Beder, Martin Neumann, Monika Brüggemann, Nicola Gökbuget, Claudia Baldus
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Springer 2026-02-01
Цуврал:	Annals of Hematology
Нөхцлүүд:	Acute leukemia Acute lymphoblastic leukemia (ALL) Venetoclax Blinatumomab Bispecific antibody BH3 mimetics
Онлайн хандалт:	https://doi.org/10.1007/s00277-026-06883-8
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!